Analysts Remain Bullish on Gossamer Bio (GOSS) Citing Undervaluation

Gossamer Bio Inc. (NASDAQ:GOSS) is one of the best stocks under $3 to invest in. On February 4, H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Gossamer Bio and set a $10 price target on the stock. This ratings confirmation followed Barclays’ coverage initiation on Gossamer Bio Inc. (NASDAQ:GOSS) with an Overweight rating and $9 price target, as part of its coverage assumption of 12 biotech stocks. Barclays claimed in its report that biotech stocks like Gossamer Bio remain undervalued and that companies in the industry could benefit greatly from continued mergers and acquisitions, and healthy fundamentals.

Gossamer Bio Inc. (NASDAQ:GOSS), NASDAQ:GOSS, Yahoo Finance,

Cantor Fitzgerald also has an Overweight rating on Gossamer Bio Inc. (NASDAQ:GOSS), which was reiterated in its January 22 report. The analyst noted that results for its ongoing clinical trial of seralutinib in pulmonary arterial hypertension will likely come out in mid to late February, with additional imaging data scheduled to be presented in the second quarter of 2026.

Gossamer Bio Inc. (NASDAQ:GOSS) is a pharmaceutical company specializing in the discovery, development, and marketing of treatments in the medical fields of immunology, inflammation, and oncology.

While we acknowledge the risk and potential of GOSS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GOSS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 11 Best Stocks Under $3 to Buy Right Now and  10 Most Undervalued Stocks to Buy and Hold for 5 Years

Disclosure: None. This article is originally published at Insider Monkey.